What recent research tells us about GLP-1 medications

A class of medications known as GLP-1 receptor agonists has become one of the most widely discussed topics in metabolic health over the past two years. Here is a plain-language summary of where the research currently stands.

What GLP-1 medications are

GLP-1, short for glucagon-like peptide-1, is a hormone the body produces naturally after eating. It helps regulate blood sugar and signals fullness to the brain. GLP-1 receptor agonists are medications that mimic this hormone. They were originally developed for the management of type 2 diabetes and are administered as a once-weekly injection under the supervision of a clinician.

What the recent studies show

Large clinical trials published in peer-reviewed journals over the last several years have reported that, when used as prescribed and combined with lifestyle support, this class of medications can contribute to meaningful improvements in blood-sugar control and body-weight management for appropriate candidates. Researchers continue to study long-term outcomes, including cardiovascular and kidney-related endpoints.

As with any medication, results vary from person to person, and these treatments are not appropriate for everyone. Common side effects reported in trials include nausea, reduced appetite, and gastrointestinal discomfort, particularly during the first weeks of treatment.

Who should consider talking to a clinician

Health authorities generally suggest that decisions about any prescription medication be made in consultation with a qualified healthcare provider, who can review medical history, current medications, and overall goals. People who are pregnant, breastfeeding, or who have certain endocrine conditions may not be candidates.

Where to learn more

Readers interested in additional, plain-language information about telehealth options for weight management can review the following informational resource.